Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
1,787 JPY | -1.24% | -0.06% | -10.94% |
Sales 2024 * | 1,559B 10.77B | Sales 2025 * | 1,674B 11.56B | Capitalization | 3,244B 22.4B |
---|---|---|---|---|---|
Net income 2024 * | 140B 968M | Net income 2025 * | 199B 1.37B | EV / Sales 2024 * | 2,37x |
Net Debt 2024 * | 449B 3.1B | Net Debt 2025 * | 317B 2.19B | EV / Sales 2025 * | 2,13x |
P/E ratio 2024 * | 23,7x | P/E ratio 2025 * | 16,2x | Employees | 14,484 |
Yield 2024 * | 3,87% | Yield 2025 * | 4,16% | Free-Float | 98.82% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -1.24% | ||
1 week | -0.58% | ||
Current month | -0.58% | ||
1 month | +0.22% | ||
3 months | -19.05% | ||
6 months | -20.93% | ||
Current year | -10.94% |
1 week
1 777.00
1 814.00

1 month
1 748.00
1 839.50

Current year
1 748.00
2 360.50

1 year
1 748.00
2 360.50

3 years
1 470.00
2 360.50

5 years
1 356.00
2 360.50

10 years
1 062.00
2 360.50

Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 1986 |
Kenji Yasukawa
CHM | Chairman | 63 | 1986 |
Minoru Kikuoka
DFI | Director of Finance/CFO | 61 | 2022 |
Members of the board | Title | Age | Since |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 66 | 2021 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 2017 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 1986 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.47% | 7 M€ | +2.67% | ||
4.85% | 11 M€ | +23.50% | ||
4.85% | 10 M€ | +24.54% | ||
4.85% | 4 M€ | -.--% | ||
4.85% | 1 M€ | +21.66% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-12-07 | 1,787 | -1.24% | 6 486 200 |
23-12-06 | 1,809.5 | +1.06% | 5,238,500 |
23-12-05 | 1,790.5 | -0.17% | 5,357,400 |
23-12-04 | 1,793.5 | -0.72% | 5,674,500 |
23-12-01 | 1,806.5 | +0.50% | 4,955,600 |
Delayed Quote Japan Exchange, December 07, 2023 at 01:00 am EST
More quotes
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Sector
Pharmaceuticals
Calendar
2024-01-30
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
A
Sell
Buy

Mean consensus
BUY
Number of Analysts
15
Last Close Price
1,809.5JPY
Average target price
2,610JPY
Spread / Average Target
+44.24%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.94% | 22 027 M $ | |
+61.07% | 530 B $ | |
+43.20% | 438 B $ | |
-11.34% | 377 B $ | |
-4.79% | 268 B $ | |
-9.42% | 258 B $ | |
-13.34% | 230 B $ | |
+0.55% | 200 B $ | |
-9.56% | 198 B $ | |
-43.81% | 163 B $ |